PR Newswire · Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
AI summary
Summary by Wenlo · not part of the original release
Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. The investigation focuses on whether the company and certain officers engaged in securities fraud or unlawful business practices. On October 29, 2026, Alnylam reported slowing demand for its treatment Amvuttra and lower total transthyretin demand growth of $81 million for the third quarter ended September 30, 2026. Following this news, Alnylam's stock price fell $58.40, or 25.13%, to close at $174.00.
AI summaries can miss details: read the full release below. Not investment advice.
Original release from PR Newswire
As distributed by PR Newswire, unedited.
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On October 29, 2026, Alnylam reported its financial results for the third quarter ended September 30, 2026. Among other items, the Company reported slowing demand for one of its transthyretin-mediated amyloidosis treatments, Amvuttra, which accounts for 87.5% of Alnylam's product sales. Alnylam announced U.S. total transthyretin demand growth of $81 million, compared to $129 million for the preceding quarter.
On this news, Alnylam's stock price fell $58.40, or 25.13%, to close at $174.00 on October 29, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-alnylam-pharmaceuticals-inc---alny-302937383.html
SOURCE Pomerantz LLP
